We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Nicole LeBoeuf

Nicole R. LeBoeuf MD, MPH

Clinical Director, Cutaneous Oncology; Director, Program in Skin Toxicities for Anticancer Therapy, Dana-Farber Cancer Institute; Assistant Professor, Dermatology, Harvard Medical School, Boston, Massachusetts

Dr. LeBoeuf received her medical degree from the University of Massachusetts Medical School in 2006.  She completed her residency in Dermatology at Columbia University, where she served as Chief Resident, followed by a fellowship in Cutaneous Oncology at Brigham and Women’s/Dana-Farber Cancer Center at Harvard. Dr. LeBoeuf earned a Masters in Public Health from the Harvard TH Chan School of Public Health in 2015.  She established and directs the Program in Skin Toxicities from Anticancer Therapies at the Dana-Farber/Brigham and Women’s Cancer Center.  She is the Clinical Director for the Center for Cutaneous Oncology, where leads clinical trials in cutaneous lymphoma and rare skin malignancies as well as interventional studies for the prevention or management of side effects from cancer treatment.  Her research focuses on understanding the immunologic mechanisms of side effects from cancer therapeutics and implementing therapies or other interventions to mitigate them. 

Disclosures

Dr. LeBoeuf is a consultant for Bayer HealthCare Pharmaceuticals, Inc., Fortress Biotech, Sanofi US Services, Inc., and Seattle Genetics, Inc. 

Recent Contributions to PracticeUpdate:

  1. Immune Checkpoint-Mediated Psoriasis